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Abstract
Background: Toxoplasma gondii has been shown to trigger strong cellular immune responses to heterologous
antigens expressed by the parasite in the inbred mouse model [1]. We studied the immune response induced by
T. gondii as an effective vaccine vector in chickens and rabbits.
Results: T. gondii RH strain was engineered to express the yellow fluorescent protein (YFP) in the cytoplasm. A
subcutaneous injection of the transgenic T. gondii YFP in chickens afforded partial protection against the infection
of transgenic E. tenella YFP. T. gondii YFP induced low levels of antibodies to YFP in chickens, suggesting that YFP
specific cellular immune response was probably responsible for the protective immunity against E. tenella YFP
infection. The measurement of T-cell response and IFN-g production further confirmed that YFP specific Th1
mediated immune response was induced by T. gondii YFP in immunized chickens. The transgenic T. gondii
stimulated significantly higher YFP specific IgG titers in rabbits than in chickens, suggesting greater
immunogenicity in a T. gondii susceptible species than in a resistant species. Priming with T. gondii YFP and
boosting with the recombinant YFP can induce a strong anti-YFP antibody response in both animal species.
Conclusions: Our findings suggest that T. gondii can be used as an effective vaccine vector and future research
should focus on exploring avirulent no cyst-forming strains of T. gondii as a live vaccine vector in animals.
Background
A variety of viruses and bacteria have been used suc-
cessfully as live vaccine vectors [2-6]. The antigen deli-
vering efficiency and the type of immune response of
live vaccine vectors depends on their replication at
infected sites and in target cells [7]. An effective live
vaccine vector should have the capacity to infect a wide
range of target cells with high efficiency and present
effectively heterologous antigens to T cells. In addition,
a live vaccine vector should also satisfy the requirement
of safety and the ease of transfection of foreign DNA
into the vector [8].
Toxoplasma gondii is an obligate intracellular parasite.
It can infect any nucleated cells of warm-blood verte-
brates [9-12] and induce strong humoral, mucosal and
cellular immune responses, making it an attractive sys-
tem for delivering heterologous antigens [9]. Avirulent
strains of T. gondii have been tested to immunize
livestock and studied in experimental animals to prevent
congenital toxoplasmosis [13]. A commercial live S48
strain vaccine (Ovilis. Toxovax
®) for veterinary use has
already been approved in some countries [14-16].
Because of the strong immunogenicity, availability of
avirulent strains and the ease of genetically engineering
stable parasite lines, T. gondii has the potential to be
explored as a live vaccine vector for bacterial, viral and
parasite pathogens [17].
Studies on the immune response to T. gondii infection
have been conducted extensively in the mouse [1,18,19].
Green fluorescent protein (GFP) has been extensively
utilized as the reporter protein in genetic manipulation
[20-22], and it was also used as a model antigen to
study the antigen delivery to target the specific immune
response pathway [23]. We posed the following ques-
tions: (-) Could foreign antigens expressed by T. gondii
stimulate antigen-specific protective immune responses
in chickens; (-) whether there is any difference in anti-
gen specific immune responses induced by transgenic T.
gondii in chickens, which are naturally resistant to T.
* Correspondence: suoxun@cau.edu.cn
1National Animal Protozoa Laboratory, College of Veterinary Medicine, China
Agricultural University, Beijing, 100193, China
Full list of author information is available at the end of the article
Zou et al. Parasites & Vectors 2011, 4:168
http://www.parasitesandvectors.com/content/4/1/168
© 2011 Zou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.gondii infection, and rabbits, which are susceptible to T.
gondii infection.
In this study, we developed a transgenic T. gondii that
expressed the yellow fluorescent protein (YFP), a yellow
version of GFP [24], as a model antigen. We firstly
demonstrated that the transgenic T. gondii YFP elicited
YFP-specific immune responses that conferred partial
protection against a challenge with YFP-expressing E.
tenella. We also showed that immunization with trans-
genic T. gondii YFP induced greater YFP-specific
humoral immune responses in rabbits than in chickens.
Our data have obvious implications on the utilization of
T. gondii or other apicomplexa protozoa as a live vac-
cine vector. A commercial live vaccine strain S48 or
avirulent no cyst-forming strains of T. gondii need to be
used to explore T. gondii as a live vaccine vector in ani-
mals in the future study.
Materials and methods
Parasite
The wild type RH strain of T. gondii and its stably
t r a n s f e c t e dl i n ew e r em a i n t a i n e db ys e r i a lp a s s a g e si n
African green monkey kidney (VERO) (Shanghai Insti-
tutes For Biological sciences, CAS) cells in DMEM sup-
plemented with FBS (10% v/v), penicillin (200 U ml
-1)
and streptomycin (20 mg ml
-1)i nah u m i d i f i e d
atmosphere of 5% CO2 at 37°C. Stable YFP-transfected
Eimeria tenella (E. tenella YFP) was constructed, main-
tained and propagated in coccidia-free 4-day-old AA
broilers [25], briefly YFP expression vector was trans-
fected into the wild type E. tenella sporozoites, and the
transfected sporozoites were inoculated into chickens.
At 6-9 days post-infection, oocysts were collected from
feces of chickens according to procedures described pre-
viously [26]. The YFP positive oocysts were sorted by a
MoFloTM cell sorter (Dako Cytomation, Denmark) four
times until the percentage of fluorescent oocysts reached
90%.
Plasmid construct
The pTgmicYFP plasmid was constructed from the
pTgsagYFP, which was previously constructed in our
laboratory [27]. The sag1 promoter of T. gondii was
replaced by the T. gondi microneme 2 (MIC2) promoter
(1.48 kb) before the insertion of the YFP reporter gene
within the 5’ sequence of MIC2 and 3’ sequence of
SAG1 of T. gondii (Figure 1A).
Transgenic T. gondii
The RH strain T. gondii tachyzoites were propagated,
harvested and purified according to established proto-
cols [28]. Freshly purified tachyzoites were suspended in
Figure 1 Expression of yellow fluorescent protein (YFP) by T. gondii transfected with the pTgmicYFP plasmid.A ,P l a s m i dm a po f
pTgmicYFP. B, Western blot of YFP expressed by the transgenic T. gondii YFP (TgYFP) and wild type T. gondii (WT) using the rabbit anti-GFP
antisera and a sheep anti-rabbit IgG HRP-conjugate. C, T. gondii YFP in murine macrophages observed by fluorescence microscopy, confirming
the location of YFP by T. gondii YFP. D, Fitness of T. gondii YFP and wild type T. gondii at a ratio of 7:3 in mice.
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5×1 0
7 ml
-1. The pTgmicYFP plasmid was linearized
with the restriction endonuclease BglII and transfected
to the parasites by electroporation [29]. Fifty-150 μl line-
arized pTgmicYFP, 100 U BglII and 1 × 10
7 tachyzoites
in a 4 mm cuvette were subjected to electroporation
(Gene Pulser II™,B i o - R a d ,U S A )a tap e a kv o l t a g eo f2
kV and a capacitance of 25 μF. After electroporation,
the parasites were left undisturbed at room temperature
for 20 min and then inoculated onto confluent MDBK
or VERO cells (Shanghai Institutes For Biological
sciences, CAS) in the modified DMEM medium.
The transfected tachyzoites were released and sorted
b yaM o F l o ™cell sorter (Dako Cytomation, Denmark),
and the sorted tachyzoites were cultured again in
MDBK or VERO cells. After about five passage-sorting
cycles, the transgenic line, named as T. gondii YFP was
cloned by limiting dilution in 96-well plates [28].
YFP expression in the transfected tachyzoites was veri-
fied by Western blotting. The transgenic and wild para-
sites were harvested from VERO cells, lysed in SDS
sample buffer, and boiled for 10 min. The YFP protein
was identified by Western blotting using rabbit anti-
GFP antisera (Proteintech, China), goat anti-rabbit IgG
conjugated to alkaline phosphatase (Proteintech, China)
and chemiluminescent detection (CWBIO, China).
YFP expression by the transgenic line in vivo was stu-
died in mice. The transgenic T. gondii YFP was propo-
gated in Balb/c mice by i.p. inoculation with 1 × 10
4
tachyzoites per animal. Replicating T. gondii YFP tachy-
zoites in murine macrophages were harvested from the
peritoneal cavity with 4 ml of sterile saline 3 days after
inoculation. Parasites in intact macrophages were exam-
ined by fluorescence microscopy with 488 nm excitation
and 508 nm emission filters.
To determine the fitness of T. gondii YFP, the trans-
genic and wild type T. gondii at a ratio of 7:3 were
inoculated i.p. to mice at 10
4/animal. The proportion of
T. gondii YFP, which were harvested from the peritoneal
cavity 3-5 days after inoculation, was measured by FACS
after each passage in mice.
Tachyzoite antigens preparation and expression of YFP
proteins in bacteria
A crude extract of proteins was obtained by repeated
freezing and thawing of 2 × 10
8 RH tachyzoites in liquid
nitrogen. The lysates were centrifuged at 5000 × g for
20 min at 4°C and the supernatants were collected. The
YFP gene was cloned from the pTgtubNP-YFP/sagCAT
vector [30]. The cloned gene was inserted into the pET-
21a vector (Novatech, France). The resulting plasmid
was transformed to E. coli BL21 (DE3) cells (Transgen
Company, China) with ampicillin selection. The recom-
binants were harvested after 6 h of induction with IPTG
(Isopropyl b-D-1-Thiogalactopyranoside). The YFP pro-
tein was purified using a His bind buffer kit (Novatech,
France).
Animals and immunization
AA broiler chickens were separately caged in an air-con-
ditioned room. The 15-day-old chickens (n = 10) were
immunized s.c. or i.m. with the transgenic or wild type
T. gondii (5 × 10
6/chicken) in complete cytomix buffer
(CCB), 160 μg recombinant YFP emulsified in Freund
complete adjuvant (FCA) or CCB. Female New Zealand
white rabbits (90 days of age) were inoculated with 1 ×
10
7 parasites. The immunized or non-immunized chick-
ens and rabbits were boosted i.m. with 160 μg (chicken)
or 500 μg (rabbit) YFP emulsified with FCA. The boos-
ter dose was administered 20 (chicken) or 35 (rabbit)
days after the primary immunization. Serum anti-YFP
antibodies were determined by ELISA 10 days after the
primary immunization or the booster immunization.
Additional groups of 10 day old white Leghorn chick-
ens (n = 10) were immunized s.c. twice with the trans-
genic or wild type T. gondii tachyzoites or160 μg
recombinant YFP emulsified in Freund complete adju-
vant (FCA) or complete cytomix buffer (un-immunized
control) at a dose interval of 15 days. The primary immu-
nization tachyzoites was 5 × 10
6, and the booster dose
was 1 × 10
7. All chickens were challenged orally with
transgenic E. tenella YFP oocysts (1 × 10
3) 15 days after
the booster immunization dose. The immune protection
of T. gondii YFP against E. tenella YFP, which carry the
same model antigen, was assessed by fecal oocyst excre-
tion and cecum lesions 9 days after the challenge.
Determination of antibody titers
Serum antigen specific IgG of the immunized chickens
or rabbits was measured by ELISA. A 96-well microtiter
plates were coated with the recombinant YFP harvested
from E. coli BL21 bacteria (described above) at 2 μg/ml
or tachyzoite antigens at 5 μg/ml in 0.05 M bicarbonate
buffer (pH 9.6) overnight at 4°C, and blocked for 2 h at
37°C with 5% milk powder (Difco™skim milk, BD) in
PBST(PBS containing 0.05% Tween 20)before washing
with PBST. Serially diluted serum samples were added
and incubated for 1 h at 37°C. Antigen-specific antibo-
dies were detected with HRP-labeled anti-chicken IgG
with 1:1000 dilution or anti-rabbit IgG with 1:5000 dilu-
tion in 2% milk-PBST for 1 h at 37°C. The ELISA was
developed with 100 μl/well of 10 mg/ml TMB solution
in 0.025 M phosphate-citrate buffer (Sigma). The reac-
tion was stopped by 0.2 M H2SO4 and the optical den-
sity (OD) at 450 and 630 nm was measured by a plate
reader (Bio-Rad, CA, USA). The serum antibody titer
was defined as the highest dilution that gave a test/naïve
serum OD ratio of 2.1 or higher.
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Three chickens of each group were sacrificed on the
12th day after immunization. Single-cell suspensions
derived from spleen in RPMI-1640 plus 10% FCS were
prepared and loaded onto 6-well cell cultured plates
(10
7 cells per well). The cells were incubated at 41°C in
a5 %C O 2 incubator. The cells were stimulated for 16 h
with rYFP (5 μg/ml). Total RNA was extracted with Tri-
zol
® (Invitrogen) and then transcripted using High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems). The primer pairs used for analysis of cDNA
were showed in Table 1. Quantitative real-time PCR was
performed on the 7500 Real Time PCR System (Applied
Biosystems) with a program of 50°C for 2 min, 95°C for
10 min and 40 cycles of 95°C for 15 s; 60°C for 1 min.
For each sample, template copy numbers were internally
normalized with their respective input control. Relative
expression was calculated as the ratio of template copy
numbers of a sample relative to the naive control after
normalizing to their respective isotype control Actin.
Histological examination
The cecum of the challenged chickens was collected and
fixed in 2.5% (v/v) glutaraldehyde-polyoxymethylene
solution immediately after euthanization. The tissue
samples were dehydrated and embedded in paraffin wax.
Serial paraffin sections (4 um) were obtained and incu-
bated at 37°C for at least 12 h. Paraffin was removed by
three consecutive washings in xylol for 5 min each, and
then hydrated with in 100, 95, 80, 70 and 50% alcohol
and then deionized water. The histological paraffin sec-
tions were stained with Hematoxylin & Eosin (HE) and
examined under a light microscope.
Statistical analysis
The data were analyzed using the one-sided student’st -
test. A P value less than 0.05 or 0.01 was considered
significant.
Results
Transgenic T. gondii expressing the heterologous protein
YFP
We engineered transgenic T. gondii expressing YFP as a
model antigen by transfection of T. gondii RH with the
plasmid pTgmicYFP containing a strong MIC2
promoter (Figure 1A). A stable transgenic line was
cloned after several passages in mice and FACS sorting
and limiting dilution. The exotic YFP protein expression
was confirmed by western blotting. The transgenic T.
gondii produced an expected band of 54.6 kDa protein
recognized by anti-GFP antibodies, while no positive
band was detected for the wild type T. gondii (Figure
1B). Fluorescence microscopy showed that T. gondii
YFP expressed abundant YFP protein which was located
in the cytoplasm of the parasites (Figure 1C). The trans-
genic T. gondii was co-passaged with the wild type T.
gondii in mice and the proportion of the two lines
remained constant after 4 passages (Figure 1D); this
indicated that the fitness of the transgenic parasites was
not altered after the integration of the exotic DNA into
the parasite genome.
Immunization with transgenic T. gondii YFP conferred
partial protection against challenge with E. tenella YFP
It has been shown that immunization of inbred mice with
transgenic T. gondii expressing a foreign antigen of micro-
organisms can provide highly effective priming for CD8 T
cell-dependent protective immunity against the microor-
ganisms [1,18]. The YFP specific protective immune
response was studied in chickens by immunization with T.
gondii YFP followed by challenging with transgenic E.
tenella YFP expressed in the cytoplasm (Figure 2A).
Immunization with T. gondii YFP provided partial protec-
tion against E. tenella expressing the same antigen, YFP.
Fecal oocyst output was significantly lower in the T. gondii
YFP-immunized chickens than the wild type T. gondii-
immunized or un-immunized chickens. The latter two
groups yielded comparable number of oocysts. Compared
with the rYFP immunized group, there was a decrease in
fecal oocyst output in the T. gondii YFP-immunized chick-
ens; although the small decrease in fecal oocyst output
was not statistically significant (Figure 2B).
Histological examination of the cecum showed shedding
of mucosal cells and inflammatory cell infiltration of the
lamina propria in all groups, but the lesions in the trans-
genic T gondii group were less severe than the wild type
and naïve groups and comparable to the rYFP immunized
group (Figure 2C). These data suggest that the transgenic
T. gondii YFP can elicit YFP specific immune responses in
chickens. Previous studies showed that poultry are pro-
tected from coccidiosis mainly by cellular immunity
[31,32]. The protection against E. tenella YFP infection in
chickens observed in this study indicated that T. gondii
YFP induced YFP specific cellular immunity.
Humoral immune responses of chickens and rabbits to
the transgenic T. gondii
Here we investigated YFP specific humoral immune
response in chickens and rabbits immunized with the
Table 1 Primer sequences used in Real-time RT-PCR
Sequence no Gene name Primer sequence
1 IFN-g F- CGCACATCAAACACATATCTG
R- GATTCTCAAGTCGTTCATCGG
2 IL-4 F-AGGCAACACTACTTCAATGG
R-GCTAGTTGGTGGAAGAAGGT
3 Actin F-CCACACTTTCTACAATGAGCTG
R-GGTCTCAAACATGATCTGTGTC
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nized s.c. or i.m. with 5 × 10
6 transgenic or wild type T.
gondii tachyzoites (WT), 160 μg rYFP emulsified in FCA
or CCB. Chickens primed with T. gondii YFP developed
YFP-specific IgG, and the levels of anti-YFP IgG were
significantly higher than those in chickens primed with
wild type T. gondii or CCB (Figure 3A). Serum antibody
titers in chickens injected i.m. with the transgenic para-
sites were comparable with the titers in chickens immu-
nized by the s.c. route (Figure 3B). However, YFP
specific antibody titers in chickens immunized with the
transgenic parasites were markedly lower than those in
chickens immunized with the rYFP protein (Figure 3C).
Next, we investigated the humoral immune response in
a susceptible animal model, the rabbit, to the transgenic
T. gondii. Rabbits were immunized s.c. with 1 × 10
7 T.
gondii YFP or WT strain, and serum antibodies to YFP
and tachyzoite antigens were measured. A subcutaneous
injection of the transgenic parasite elicited high levels of
YFP specific antibodies, The IgG titers peaked on day
25 post immunization (Figure 3D). Compared with YFP
specific antibodies, the host produced higher level of
IgG to tachyzoite antigens (Figure 3D).
Prior immunization with T. gondii YFP had no impact
on humoral immune response to rYFP in either animal
species. Similar serum YFP specific antibody titers were
measured in chickens and rabbits injected with rYFP
with or without prior immunization with T. gondii YFP
(Figure 4). The above findings suggest that a subunit
vaccine may be utilized to induce high level of humoral
immune response in some animal species to make up
for the low IgG titre induced by transgenic T. gondii.
Figure 2 The partial protection against challenge with Eimeria tenella YFP (EiYFP) in chickens which were immunized with T. gondii.
Leghorn chickens immunized s.c. with two doses of T gondii YFP (TgYFP) or wild type RH strain (5 × 10
6 for the initial immunization and 10
7 for
the booster dose) or 160 μg recombinant YFP emulsified in Freund complete adjuvant (FCA). The immunized chickens were challenged with 10
3
transgenic E. tenella YFP 15 days after the booster immunization. A. Fluorescence images of transgenic E. tenella YFP oocysts. B. Fecal oocyst
counts in chickens immunized with T. gondii YFP (TgYFP) or wild type T. gondii tachyzoites (Wild-Tg) or recombinant YFP emulsified in FCA
(rYFP) or complete cytomix buffer (un-immunized control) and challenged with the transgenic E. tenella (EiYFP). C. Histopathology of the cecum
from chickens described above in Figure B. C1 Shedding of mucosal cells (arrow); C2 Inflammatory cells infiltration of lamina propria (arrow).
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expression
To further determine the YFP specific immune response
induced by transgenic T. gondii YFP, we examined the
level of IFN-g (Th1 type) and IL-4 (Th2 type) produc-
tion by YFP specific T cells using Real-time RT-PCR.
Single cell suspensions of lymphocytes were prepared
from the spleen of the immunized chickens on day 12
after immunization, and restimulated in culture with
rYFP. The results showed that the lymphocytes from
transgenic T. gondii YFP immunized chickens produced
significantly higher level of IFN-g compared with wild
type (WT) tachyzoites immunized group, while analysis
of the IL-4 transcription revealed that there was no sig-
nificant difference between the transgenic group
(TgYFP) and the WT group (Figure 5).
Discussion
Transgenic organisms expressing model antigens (e.g.
ovalbumin, b-galactosidase) have been conveniently used
Figure 3 Priming of AA broiler chickens and rabbits with T. gondii YFP (TgYFP) elicited antigen specific antibody responses.A ,Y F P
specific IgG in chicken sera (1: 25) 10 days after immunization by s.c. injection of 5 × 10
6 transgenic (TgYFP), wild type (WT) T. gondii tachyzoites or
complete cytomix buffer (CCB). B, YFP specific IgG (1:25) 10 days after immunization by s.c. or i.m. injection. C, Serum YFP specific antibody titers in
chickens 10 days after a s.c. injection of transgenic T. gondii tachyzoites (TgYFP) or i.m. injection of recombinant YFP (rYFP) protein expressed in E.
coli. D, Kinetics of serum antibodies to YFP and tachyzoite antigens in rabbits immunized with the transgenic T. gondii. * P < 0.05, ** P < 0.01.
Figure 4 Serum YFP specific antibody titers in chickens and
rabbits immunized with T. gondii YFP and/or rYFP protein.
Chickens and rabbits were primed s.c. with 5 × 10
6 and 1 × 10
7 T.
gondii YFP tachyzoites, respectively. The primed chickens were
boosted i.m. 20 days later with 160 μg of rYFP emulsified in Freund
complete adjuvant, and the primed rabbits were boosted i.m. 35
days later with 500 μg of recombinant YFP emulsified in Freund
complete adjuvant. Serum YFP specific IgG titers were measured 10
days after the booster immunization.
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of the model antigen specific immune response are eval-
uated by challenging the host with a different virus or
bacteria strain or species expressing the same antigen
[33]. Although some studies have already begun to
explore the apicomplexan parasites as live vaccine vec-
tors [34-38], there had been no studies to use transgenic
parasites to express model antigen and induced immu-
nity against infection by other transgenic Apicomplexa
parasites, which have more complex life cycles and
express more proteins than viruses and bacteria.
Although both Eimeria tenella and Toxoplasma gondii
are intracellular Apicomplexa parasites, there are signifi-
cant differences in genome, proteome and life cycle
[39,40]. Our study showed that the transgenic T. gondii
expressing YFP induced immunity that partially pro-
tected chickens from the challenge with the transgenic
E. tenella also expressing YFP. Therefore this study
paved the way for the application of a heterologous
challenge system to apicomplexa parasites.
Variations in susceptibility of different animal species
to T. gondii infection are well known. The resistance is
probably attributable to innate immunity or a rapid and
strong immune response before the parasite can even dis-
seminate. Chickens inoculated with T. gondii do not
show any clinical symptoms [41], while rabbits are highly
susceptible to T. gondii infection [42]. Both chickens and
rabbits were chosen to evaluate the humoral immunity
induced by the transgenic T. gondii.W eo b s e r v e dt h a t
the YFP specific humoral immune response in the rabbit
was significantly higher than that in the chicken. This
implied that the susceptibility was one important deter-
minant of the strength of immune responses. It was
reported that six of seven T. gondii isolates from chickens
were avirulent in mice, suggesting that the chicken was
possibly more susceptible to avirulent T. gondii infection.
Therefore, the avirulent T. gondii strain may be an effec-
tive vaccine vector for chickens.
It was reported that subunit vaccines predominantly
induced high level neutralizing antibodies. To enhance
the humoral immune response induced by the trans-
genic T. gondii in resistant animals, chickens immunized
with T. gondii YFP were boosted with the YFP protein.
The combined immunization regimen induced a high
level humoral response in chickens compared to the
weak humoral immunity induced by the transgenic
parasite alone. Chicken whether or not they are vacci-
nated with T. gondii YFP prior to injection with rYFP
produce the equivalent titers of anti-YFP antibody, this
may be due to the superior ability of rYFP emulsified in
FCA to induce high antibody titer which makes the
effect of a boost is not visible. For the elicitation of
strong cellular and humoral immune responses by trans-
genic T. gondii, the immunization with a combination of
trangesnic parasites-based vaccine and a subunit vaccine
should be considered.
Some intracellular pathogens have the coding capacity
to produce distinct proteins that are sorted into differ-
ent intracellular compartments [43,44]. Studies have
shown that only a few proteins of T. gondii can stimu-
late CD8 T cell-dependent immunity in mice model
[44,45]. Secreted, not cytoplasmic, antigens of T. gondii
primed IFN-g expressing CD8 T cells in mice which was
susceptible to T. gondii infection [46]. Chicks, which
were resistant to T. gondii infection, have many immu-
nological mechanisms in common with mammals but
have evolved distinct immunity to pathogens [47]. Here
we showed that cytoplasm-localized YFP expressed by
T. gondii can produce protective immune response in
chicks that conferred partial protection against challenge
with E. tenella YFP. To investigate whether this partial
protection was related to the cytoplasm localization of
YFP, a transgenic T. gondii line which secreted YFP
need to be constructed in the future study to investigate
the influences of antigen compartmentalization on the
immune response in chickens.
Conclusions
In conclusion, our study demonstrated the feasibility of
using T. gondii as a delivery system to induce antigens
specific protective immunity against the heterologous
Figure 5 IFN-g and IL-4 mRNA transcripts level of spleen
lymphocytes. The spleen lymphocytes were isolated on day 12
after immunization, and restimulated in culture for 16 h with rYFP,
IFN-g and IL-4 mRNA transcripts level was measured by Real-time
RT-PCR.
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priming and subunit vaccine boosting approach would
be more effective than immunization with the trans-
fected parasites alone in some animal species. The opti-
mizations of T. gondii as a live vaccine vector to
enhance the immune response need to be conducted in
the future study.
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